Source: Medpick
  • Avisa Diagnostics (AVBT)  intends to raise approximately C$375,000 from a non-brokered private placement
  • The company will issue 1.39 million shares to an eligible purchaser outside of Canada and the US
  • Avisa Diagnostic is a clinical-stage medical device company developing the Avisa BreathTest™
  • Avisa Diagnostics Inc. (AVBT) is unchanged, trading at $0.30 per share at 4 pm ET

Avisa Diagnostics (AVBT)  intends to conduct a non-brokered private placement of 1,390,000 common shares to raise approximately C$375,000.

The offering is expected to close on or about July 15.

Avisa intends to use the net proceeds from the offering for operations and expansion of its business and for general working capital purposes.

The offering is being made to an eligible purchaser resident in a jurisdiction other than Canada and the United States. The shares will not be subject to resale restrictions in Canada.

Avisa Diagnostic is a clinical-stage medical device company developing the Avisa BreathTest™, a novel drug/device biomarker technology platform.

Avisa Diagnostics Inc. (AVBT) is unchanged, trading at $0.30 per share at 4 pm ET.

More From The Market Online

Cancer-fighting pharma stock eyes 2027 regulatory approval

Theralase Technologies (TSXV:TLT), a cancer-fighting pharma stock, expands its team with two clinical research associates.

PharmaDrug-PharmaTher Holdings JV submits clinical, regulatory package

Sairiyo Therapeutics, a PharmaDrug (CSE:PHRX) and PharmaTher Holdings (CSE:PHRM) joint venture, pursues a human clinical study in Australia.

WELL Health and Microsoft to future-proof North American healthcare

WELL Health Technologies (TSX:WELL) and Microsoft (NDAQ:MSFT) sign a five-year deal to expedite healthcare's transition into the digital age.